Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration;Intravitreales Bevacizumab vs. Verteporfin und Intravitreales Triamcinolon Acetonid bei Patienten mit Neovaskulärer AMD

Ophthalmologe

Volumn 104, Issue 7, 2007, Pages 588-593

  Hahn, R ^a   Sacu, S ^a   Michels, S ^a   Varga, A ^a   Weigert, G ^a   Geitzenauer, W ^a   Vecsei Marlovits P ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bevacizumab; Neovascular age related macular degeneration; PDT; Triamcinolone acetonide; Vascular endothelial growth factor

Indexed keywords

EID: 34547436733     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-007-1547-4     Document Type: Article

References (30)

1. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidalneovascularisation in age-related macular degeneration. Am J Ophthalmol 141: 638-645
2. Azab M, Boyer DS, Bressler NM et al. (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123: 448-457
3. Blinder KJ, Bradley S, Bressler NM et al. (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136: 407-418
4. Bressler NM, Arnold J, Benchaboune M et al. (2002) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120: 1443-1454
5. Chapman JA, Beckey C (2006) Pegaptanib: a novel approach to ocular neovascularization. Ann Pharmacother 40: 1322-1326
6. Costa RA, Jorge R, Calucci D et al. ( in press) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol: Epub ahead of print
7. Dhalla MS, Shah GK, Blinder KJ et al. (2006) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26: 988-993
8. Fackler TK, Reddy S, Bearelly S et al. (2006) Retrospective review of eyes with neovascular age-related macular degeneration treated with photodynamic therapy with verteporfin and intravitreal triamcinolone. Ann Acad Med Singapore 35: 701-705
9. Frank RN, Amin RH, Eliott D et al. (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122: 393-403
10. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal Bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349
11. Geitenzauer W et al. (2006) Frühe Effekte nach systemischer und intravitrealer Becacizumab Therapie bei neovaskulärer altersbedingter Makulagegeneration. Klin Monantsbl Augenheilkd 223: 822-827
12. Heier JS, Boyer DS, Ciulla TA et al. (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 124: 1532-1542
13. http://www.do.org/publikationen/DOG_Empfehlung_Intravitreale_Injektionen. pdf
14. Iqbal S, Lenz HJ (2004) Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol (Suppl 1) 54: S32-S39
15. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245: 68-73
16. Meads C, Hyde C (2004) Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol 88: 212-217
17. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U (2006) Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 47: 371-376
18. Moschos MM, Brouzas D, Apostolopoulos M et al. (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study: Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114: 37-44
19. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002.e1-e12
20. Narayanan R, Mungcal JK, Kenney MC et al. (2006) Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 47: 722-728
21. Ramratten RS, Schaft TL van der, Mooby CM et al. (1994) Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroids in aging. Invest Ophthalmol Vis Sci 35: 2857-2864
22. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19: 361-372
23. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA (2006) Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 26: 602-612
24. Schmidt-Erfurth U, Langmann G, Kieselbach G et al. (2005) Empfehlungen zur Vorgehensweise bei intravitrealen Injektionen. Spektrum der Augenheilkunde 19: 68-71
25. Schmidt-Erfurth UM, Gabel P, Hohman T (2006) PROTECT Study Group. Preliminary Results From an Open-Label, Multicenter, Phase II Study Assessing the Effects of Same Day Administration of Ranibizumab (Lucentis) and Verteporfin IOVS ARVO E-Abstract 2960
26. Shyong MP, Lee FL, Chen SJ et al. (2005) Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. J Chin Med Assoc 68: 419-424
27. Spaide RF, Laud K, Fine HF et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390
28. Wachtlin J, Stroux A, Wehner A et al. (2005) Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp Ophthalmol 243: 438-445
29. Wickens J, Blinder KJ (2006) Preliminary benefit-risk assessment of verteporfin in age-related macular degeneration. Drug Saf 29: 189-199
30. Wormwald R, EvansJ, Smeeth L, Henshaw K (2005) Photodynamic therapy for neovascular age-related macular degeneration. Chochrane Database Syst Rev 4: CD002030